For decades, mergers and acquisitions (M&A) have fueled the development and delivery of breakthrough treatments for complex diseases with a high unmet need.
A new resource from the Partnership for the U.S. Life Science Ecosystem (PULSE) spotlights this unique and vital role of M&A in America’s life sciences industry, enabling companies of all sizes to partner and merge their resources, expertise, finances and infrastructure to deliver innovative treatments to patients.
By supporting the pro-competitive partnerships that bring these and other life-changing treatment to patients, lawmakers can help sustain America’s global leadership in life sciences innovation.
This new resource highlights three examples from PULSE’s “Innovations Advanced by M&A” content series of therapies made possible by M&A, including:
- Spark Therapeutics’ gene therapy for inherited blindness
- Juno Therapeutics’ CAR-T treatment for blood cancer
- Alexion’s therapies for paroxysmal nocturnal hemoglobinuria